Greenyn Biotechnology Launches Insumate® mcIRBP-19, Targets Health Sector

Greenyn Biotechnology Co., Ltd., a publicly listed company based in Taiwan, has launched its flagship product, Insumate® mcIRBP-19 Bitter Melon Peptide, aimed at the rapidly growing health supplement market. This product has gained significant recognition, being the only bitter melon peptide globally certified by the FDA-NDI, the Taiwan Complementary Medicine Society (TCMS), and other prestigious bodies.

The launch comes at a time when global demand for scientifically validated ingredients for metabolic health is surging. According to the International Diabetes Federation, approximately 589 million adults are currently living with diabetes, a figure projected to rise to 853 million by 2050. This growing health crisis underscores the need for effective solutions, and Insumate® is positioned to meet that demand.

Recognition and Certification Pave the Way

Dr. Pang-Kuei Hsu, General Manager and R&D lead at Greenyn Biotechnology, stated that the “Excellent Product Quality Certification” from TCMS validates Insumate® as a trusted reference for healthcare professionals. This certification ensures that the ingredient has undergone rigorous evaluations of its raw materials, manufacturing processes, and clinical research.

Greenyn’s innovative approach involved over a decade of collaboration with medical schools and research institutions in Taiwan. The company utilized low-temperature supercritical extraction to isolate the bioactive mcIRBP-19 peptide from bitter melon. This method preserves the integrity and bioactivity of the peptide, setting Insumate® apart from products created using conventional extraction techniques.

Clinical Evidence Supports Efficacy

Research from Greenyn indicates that mcIRBP-19 has a unique interaction with insulin receptors, activating signaling pathways that enhance glucose utilization. Clinical studies conducted in Taiwan showed that participants consuming mcIRBP-19 for 12 weeks experienced significant improvements in their glucose control metrics.

Dr. Tao-Ming Chen, President of the TCMS, emphasized the importance of certified products in supporting metabolic health. He noted that while many products claim to contain bitter melon, only those with TCMS certification offer consumers reliable options for daily metabolic management. Insumate® is now recognized as a clinically supported functional ingredient for long-term health strategies.

Greenyn’s commitment to research and development has resulted in over seven publications in prestigious scientific journals and three large-scale clinical trials involving more than 200 subjects. These studies support the efficacy of Insumate® in managing blood glucose levels and improving overall metabolic health.

Market Expansion and Future Prospects

The global nutraceutical market is expected to grow substantially, from USD 458.5 billion in 2024 to USD 986.8 billion by 2032, with a compound annual growth rate (CAGR) of 10.18%. The Asia-Pacific region is anticipated to account for over 30% of this market share by 2026, driven by increasing consumer demand for evidence-backed health supplements.

Greenyn has successfully expanded into more than ten international markets, demonstrating strong acceptance and commercial viability of Insumate®. As the company continues to strengthen its presence globally, it aims to foster collaborations and navigate regulatory pathways in key regions, including Asia, the United States, and the European Union.

Dr. Hsu highlighted that Greenyn holds over 100 international patents and has developed multiple proprietary ingredients, including Antromax® Antrodia cinnamomea mycelia. The company is certified under various quality standards, including HACCP and ISO 22000, ensuring that it provides reliable and safe products for consumers.

With a focus on innovation and scientific validation, Greenyn Biotechnology is on track to become a leading provider of functional ingredients in the Asia-Pacific region and beyond, addressing the pressing need for effective health solutions in a rapidly growing market.